SrdanVerstovsekMD

Oncology • Houston, TX

Hematologic Oncology

Physician

Join to view full profile

Are you Dr. Verstovsek?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 51 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Summary

Dr. Srdan Verstovsek, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center.

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1998 - 2001
University at BuffaloResidency, Internal Medicine, 1995 - 1998
University of Zagreb Faculty of MedicineClass of 1992

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 1999 - 2026
OK State Medical License 2020 - 2021
IA State Medical License 1997 - 2000

Clinical Trials

Cilengitide in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2004 Jul 01
Terminated
Phase 2
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2004 Oct 01
Terminated
Phase 2
Lenalidomide for Patients With Myelofibrosis (MF) Start of enrollment: 2006 Jul 07
Completed
Phase 2
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis Start of enrollment: 2007 Apr 01
Completed
Phase 2
Pegasys® in Patients With Myeloproliferative Diseases Start of enrollment: 2005 Apr 07
Completed
Phase 2
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Start of enrollment: 2004 Jul 01
Completed
Phase 2
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Start of enrollment: 2007 Jun 01
Completed
Phase 1, Phase 2
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies Start of enrollment: 2008 Aug 01
Completed
Phase 1, Phase 2
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases Start of enrollment: 2009 May 01
Completed
Phase 1
Obatoclax for Systemic Mastocytosis Start of enrollment: 2009 Jun 01
Terminated
Phase 2
Pomalidomide for Myelofibrosis Patients Start of enrollment: 2009 Jul 22
Completed
Phase 2
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Start of enrollment: 2009 Aug 01
Completed
Phase 3
A Phase 2 Study to Evaluate the Efficacy and Safety of AB0024 in Adult Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis Start of enrollment: 2011 Feb 01
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Start of enrollment: 2010 Oct 27
Completed
Phase 3
Phase l/II Study of Ruxolitinib for Acute Leukemia Start of enrollment: 2010 Dec 01
Terminated
Phase 1, Phase 2
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients Start of enrollment: 2011 Mar 01
Completed
Phase 2
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis Start of enrollment: 2011 Sep 22
Completed
Phase 2
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF Start of enrollment: 2011 Jun 01
Completed
Phase 1, Phase 2
Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia Start of enrollment: 2013 Feb 21
Completed
Phase 2
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis Start of enrollment: 2013 Oct 01
Completed
Phase 2
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders Start of enrollment: 2014 May 01
Completed
Phase 2
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis Start of enrollment: 2016 Sep 29
Completed
Phase 2
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) Start of enrollment: 2020 Feb 07
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

4 citations
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D Bledsoe, Naval G Daver
Haematologica. 2024-08-01
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.
Tareq Abuasab, Gautam Borthakur, Rashmi Kanagal-Shamanna, Lucia Masarova, Keyur Patel
American Journal of Hematology. 2024-07-01
Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes.
Tapan M Kadia, Meixian Huang, Naveen Pemmaraju, Hussein A Abbas, Christopher Ly
NEJM Evidence. 2024-06-01

Press Mentions

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK InhibitorDecember 1st, 2022
FDA Approves Pemigatinib to Treat Rare NeoplasmsAugust 30th, 2022
FDA Approves Pemigatinib for Myeloid/Lymphoid Neoplasms With FGFR1 RearrangementAugust 26th, 2022
Join now to see all